Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969978 | 0.93 | ALDH1A1 (0.39) | CHRM1SLC6A2SLC6A4SLC6A3TMEM97 | |
| SCHEMBL18500405 | 0.89 | SLC6A4 (0.45) | CHRM1SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL19969710 | 0.86 | HTR3A (0.32) | CHRM1SLC6A2SLC6A4SLC6A3HTR3A | |
| SCHEMBL19969963 | 0.81 | HTR3A (0.41) | CHRM1SLC6A2SLC6A4LMNACYP2C9 | |
| SCHEMBL24783446 | 0.75 | SLC6A4 (0.38) | SLC6A4MEN1KMT2AALDH1A1 | |
| SCHEMBL19969960 | 0.74 | HTR3A (0.34) | CHRM1SLC6A2SLC6A4SLC6A3HTR3A | |
| SCHEMBL19090814 | 0.73 | SLC6A4 (0.30) | SLC6A4 | |
| SCHEMBL9885785 | 0.73 | SHBG (0.41) | SLC6A4CYP2C9MEN1KMT2ASIGMAR1 | |
| SCHEMBL23375445 | 0.73 | SHBG (0.41) | SLC6A4CYP2C9MEN1KMT2ASIGMAR1 | |
| SCHEMBL19969791 | 0.71 | HTR3A (0.31) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | CHRM1 328/4885SLC6A2 135/4885SLC6A4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.